Novo Nordisk Secures EU Approval for Oral Wegovy
BAGSVÆRD, Denmark, July 15, 2026 Novo Nordisk has achieved a major regulatory milestone after the European Commission (EC) granted...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BAGSVÆRD, Denmark, July 15, 2026 Novo Nordisk has achieved a major regulatory milestone after the European Commission (EC) granted...
BAGSVÆRD, Denmark, June 11, 2026 Novo Nordisk announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has...
BAGSVÆRD, Denmark, June 3, 2026 Novo Nordisk has announced the launch of Wegovy® pill (semaglutide tablets) in the United...
Bagsværd, Denmark – April 23, 2026 In a major advancement for pediatric diabetes care, Novo Nordisk announced positive Phase...
